FDA Approves First-Ever Adjuvanted, Cell-Based Vaccine for Influenza Pandemic Response in Multi-Dose Vial Presentation
by Press Release from Outbreak News Today on (#5S92Z)
Seqirus today announced that the U.S. Food and Drug Administration (FDA) has granted supplemental approval of a multi-dose vial (MDV) presentation of AUDENZTM (Influenza A(H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvanted, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic. The [...]
The post FDA Approves First-Ever Adjuvanted, Cell-Based Vaccine for Influenza Pandemic Response in Multi-Dose Vial Presentation appeared first on Outbreak News Today.